Biological and Clinical Implications of Comorbidities in Parkinson’s Disease
Open accessThe DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
A wide spectrum of comorbidities has been associated with Parkinson's disease (PD), a progressive neurodegenerative disease that affects more than seven million people worldwide. Emerging evidence indicates that chronic diseases including diabetes, depression, anemia and cancer may be implicated in the pathogenesis and progression of PD. Recent epidemiological studies suggest that some of these comorbidities may increase the risk of PD and precede the onset of motor symptoms. Further, drugs to treat diabetes and cancer have elicited neuroprotective effects in PD models. Nonetheless, the mechanisms underlying the occurrence of these comorbidities remain elusive. Herein, we discuss the biological and clinical implications of comorbidities in the pathogenesis, progression, and clinical management, with an emphasis on personalized medicine applications for PD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Poewe, W., Seppi, K., Tanner, C. M., Halliday, G. M., Brundin, P., Volkmann, J., Schrag, A.-E., & Lang, A. E. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.13 · Cited by 5,415
Epidemiology of Parkinson's disease
de Lau, L. M., & Breteler, M. M. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70471-9 · Cited by 4,110
Gut microbiota regulate motor deficits and neuroinflammation in a model of Parkinson's disease
Sampson, T. R., Debelius, J. W., Thron, T., Janssen, S., Shastri, G. G., Ilhan, Z. E., Challis, C., Schretter, C. E., Rocha, S., Gradinaru, V., et al. (2016) · Cell · doi:10.1016/j.cell.2016.11.018 · Cited by 3,622
Non-motor symptoms of Parkinson's disease: diagnosis and management
Chaudhuri, K. R., Healy, D. G., & Schapira, A. H. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70373-8 · Cited by 2,807 · cited 1×
“Several studies have established an association between PD and depression (Shiba et al., 2000; Chaudhuri et al., 2006; Pellicano et al., 2007; Postuma et al., 2012; Cooney and Stacy, 2016; Elbaz, 2016).”
BackgroundNon-motor features of Parkinson disease
Schapira, A. H. V., Chaudhuri, K. R., & Jenner, P. (2017) · Nature Reviews Neuroscience · doi:10.1038/nrn.2017.62 · Cited by 2,053
The role of dopamine in the pathophysiology of depression
Dunlop, B. W., & Nemeroff, C. B. (2007) · Archives of General Psychiatry · doi:10.1001/archpsyc.64.3.327 · Cited by 1,244 · cited 1×
“Drugs that enhance dopamine neurotransmission may be useful therapeutics for patients with treatment-resistant depression (Dunlop and Nemeroff, 2007).”
BackgroundAthauda, D., Maclagan, K., Skene, S. S., Bajwa-Joseph, M., Letchford, D., Chowdhury, K., Hibbert, S., Budnik, N., Zampedri, L., Dickson, J., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31585-4 · Cited by 889 · cited 1×
“More recently, a double-blinded and placebocontrolled trial showed that treatment with exenatide improved motor symptoms in PD patients in an off-medication state compared with those given placebo (Athauda et al., 2017a,b).”
ResultVagotomy and subsequent risk of Parkinson's disease
Svensson, E., Horváth‐Puhó, E., Thomsen, R. W., Djurhuus, J. C., Pedersen, L., Borghammer, P., & Sørensen, H. T. (2015) · Annals of Neurology · doi:10.1002/ana.24448 · Cited by 806 · cited 1×
“The linkage between PD and Crohn’s disease is interesting in light of the studies that suggest that gastrointestinal tract dysfunction may precede the onset of PD (Svensson et al., 2015; Sampson et al., 2016; Liu et al., 2017).”
BackgroundFelger, J. C., Li, Z., Haroon, E., Woolwine, B. J., Jung, M. Y., Hu, X., & Miller, A. H. (2016) · Molecular Psychiatry · doi:10.1038/mp.2015.168 · Cited by 620
Type 2 Diabetes and the Risk of Parkinson's Disease
Hu, G., Jousilahti, P., Bidel, S., Antikainen, R., & Tuomilehto, J. (2007) · Diabetes Care · doi:10.2337/dc06-2011 · Cited by 466
Alcohol, dementia and cognitive decline in the elderly: a systematic review
Peters, R., Peters, J., Warner, J., Beckett, N., & Bulpitt, C. (2008) · Age and Ageing · doi:10.1093/ageing/afn095 · Cited by 453
Vagotomy and Parkinson disease: A Swedish register–based matched-cohort study
Liu, B., Fang, F., Pedersen, N. L., Tillander, A., Ludvigsson, J. F., Ekbom, A., Svenningsson, P., Chen, H., & Wirdefeldt, K. (2017) · Neurology · doi:10.1212/wnl.0000000000003961 · Cited by 447
Endocrine disruptors in the etiology of type 2 diabetes mellitus
Alonso-Magdalena, P., Quesada, I., & Nadal, A. (2011) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2011.56 · Cited by 404 · cited 1×
“Environmental exposure to heavy metals and pesticides has been associated with an increased risk of PD (Willis et al., 2010) and Frontiers in Aging Neuroscience | www.frontiersin.org 3 December 2017 | Volume 9 | Article 394 diabetes (Chen et al., 2009; Alonso-Magdalena et al., 2011).”
BackgroundGenome-wide pleiotropy between Parkinson disease and autoimmune diseases
Witoelar, A., Jansen, I. E., Wang, Y., Desikan, R. S., Gibbs, J. R., Blauwendraat, C., Thompson, W. K., Hernandez, D. G., Djurovic, S., Schork, A. J., et al. (2017) · JAMA Neurology · doi:10.1001/jamaneurol.2017.0469 · Cited by 352
Diabetes mellitus and Alzheimer's disease: shared pathology and treatment?
Akter, K., Lanza, E. A., Martin, S. A., Myronyuk, N., Rua, M., & Raffa, R. B. (2011) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2010.03830.x · Cited by 352
Pioglitazone in early Parkinson's disease: a phase 2, multicentre, double-blind, randomised trial
(2015) · The Lancet Neurology · doi:10.1016/s1474-4422(15)00144-1 · Cited by 286
Nilotinib Effects in Parkinson’s disease and Dementia with Lewy bodies
Pagan, F., Hebron, M., Valadez, E. H., Torres-Yaghi, Y., Huang, X., Mills, R. R., Wilmarth, B. M., Howard, H., Dunn, C., Carlson, A., et al. (2016) · Journal of Parkinson’s Disease · doi:10.3233/jpd-160867 · Cited by 265
Karuppagounder, S. S., Brahmachari, S., Lee, Y., Dawson, V. L., Dawson, T. M., & Ko, H. S. (2014) · Scientific Reports · doi:10.1038/srep04874 · Cited by 264 · cited 1×
“Interestingly, treatment with nilotinib, a c-Abl inhibitor, prevented the loss of dopaminergic neurons in MPTP-treated mice (Karuppagounder et al., 2014), thus demonstrating its potential as a therapeutic target for PD.”
BackgroundSerum Iron Levels and the Risk of Parkinson Disease: A Mendelian Randomization Study
Pichler, I., Del Greco M., F., Gögele, M., Lill, C. M., Bertram, L., Do, C. B., Eriksson, N., Foroud, T., Myers, R. H., PD GWAS Consortium, et al. (2013) · PLoS Medicine · doi:10.1371/journal.pmed.1001462 · Cited by 173 · cited 1×
“It has been documented that PD patients exhibit lower serum iron levels (Savica et al., 2009; Pichler et al., 2013; Medeiros et al., 2016).”
BackgroundDiabetes Mellitus, Obesity, and Diagnosis of Amyotrophic Lateral Sclerosis: A Population-Based Study
Kioumourtzoglou, M.-A., Rotem, R. S., Seals, R. M., Gredal, O., Hansen, J., & Weisskopf, M. G. (2015) · JAMA Neurology · doi:10.1001/jamaneurol.2015.0910 · Cited by 145 · cited 2×
“, 2011), Amyotrophic lateral sclerosis (ALS; Kioumourtzoglou et al., 2015) and PD (Santiago and Potashkin, 2013b).”
BackgroundNeuropsychiatric symptoms, behavioural disorders, and quality of life in Parkinson's disease
Balestrino, R., & Martinez-Martin, P. (2017) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2016.12.060 · Cited by 135 · cited 2×
“…frequent non-motor symptoms occurring in approximately 35% of PD patients (Aarsland et al., 2011) and one of the strongest predictor of quality of life (Cummings, 1992; Gallagher et al., 2010; Balestrino and Martinez-Martin, 2017).”
BackgroundIron and Oxidative Stress in Parkinson’s Disease: An Observational Study of Injury Biomarkers
Medeiros, M. S., Schumacher-Schuh, A., Cardoso, A. M., Bochi, G. V., Baldissarelli, J., Kegler, A., Santana, D., Chaves, C. M. M. B. S., Schetinger, M. R. C., Moresco, R. N., et al. (2016) · PLOS ONE · doi:10.1371/journal.pone.0146129 · Cited by 131
Genetic determinants of hair color and parkinson's disease risk
Gao, X., Simon, K. C., Han, J., Schwarzschild, M. A., & Ascherio, A. (2009) · Annals of Neurology · doi:10.1002/ana.21535 · Cited by 116
Anemia or low hemoglobin levels preceding Parkinson disease: A case-control study
Savica, R., Grossardt, B. R., Carlin, J. M., Icen, M., Bower, J. H., Ahlskog, J. E., Maraganore, D. M., Steensma, D. P., & Rocca, W. A. (2009) · Neurology · doi:10.1212/wnl.0b013e3181bd80c1 · Cited by 87 · cited 3×
“Another study suggested that anemia might precede motor symptoms by 20 years (Savica et al., 2009).”
BackgroundFunctional relevance of ceruloplasmin mutations in Parkinson's Disease
Hochstrasser, H., Tomiuk, J., Walter, U., Behnke, S., Spiegel, J., Krüger, R., Becker, G., Riess, O., & Berg, D. (2005) · The FASEB Journal · doi:10.1096/fj.04-3486fje · Cited by 87
Redei, E. E., Andrus, B. M., Kwasny, M. J., Seok, J., Cai, X., Ho, J., & Mohr, D. C. (2014) · Translational Psychiatry · doi:10.1038/tp.2014.66 · Cited by 83 · cited 2×
“Although several molecular Frontiers in Aging Neuroscience | www.frontiersin.org 5 December 2017 | Volume 9 | Article 394 signatures have been identified in blood of patients with depression (Redei et al., 2014; Bilello et al., 2015), diagnosis of depression in PD patients remains challenging.”
BackgroundBlood donations, iron stores, and risk of Parkinson's disease
Logroscino, G., Chen, H., Wing, A., & Ascherio, A. (2006) · Movement Disorders · doi:10.1002/mds.20826 · Cited by 38 · cited 3×
“The presence of anemia in PD could be also an indicator of vitamin B12 deficiency (Madenci et al., 2012) or poor absorption of other nutrients (Logroscino et al., 2006).”
BackgroundAssociation of RAGE gene polymorphisms with sporadic Parkinson's disease in Chinese Han population
Gao, J., Teng, J., Liu, H., Han, X., Chen, B., & Xie, A. (2014) · Neuroscience Letters · doi:10.1016/j.neulet.2013.11.038 · Cited by 31
Cited by
Bloem, B. R., Okun, M. S., & Klein, C. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00218-x · Cited by 3,920
Inflammation in Parkinson’s Disease: Mechanisms and Therapeutic Implications
Pajares, M., I. Rojo, A., Manda, G., Boscá, L., & Cuadrado, A. (2020) · Cells · doi:10.3390/cells9071687 · Cited by 779
Zapała, B., Stefura, T., Wójcik-Pędziwiatr, M., Kabut, R., Bałajewicz-Nowak, M., Milewicz, T., Dudek, A., Stój, A., & Rudzińska-Bar, M. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10235698 · Cited by 44
Metadata
- Authors
- Santiago, J. A., Bottero, V., & Potashkin, J. A.
- Venue
- Frontiers in Aging Neuroscience
- Publisher
- Frontiers Media SA
- Published
- 2017-12-04
- Volume
- 9
- Pages
- 394-394
- ISSN
- 1663-4365 (ISSN-L)
- OpenAlex
- W2768823399
- Cited by
- 95
- References
- 28
- FWCI
- 3.90
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.